BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

North Carolina Biotechnology Center Release: $30K Biotech Center Loan Boosts Durham Company


12/28/2011 10:15:16 AM

RESEARCH TRIANGLE PARK, N.C., December 28, 2011 – A $30,000 loan from the North Carolina Biotechnology Center is helping NovaTarg grow in the Research Triangle Park area.

NovaTarg, founded in Durham in 2009, is developing novel pharmaceutical products targeting liver diseases and diabetes. The company received a $30,000 Company Inception Loan from the Biotech Center. The loan will help position it for raising outside funding that can advance its experimental therapies into clinical trials.

Kenneth Batchelor, Ph.D., NovaTarg’s founder, president and CEO, has spent nearly three decades in drug discovery, most recently as senior vice president at GlaxoSmithKline.

“The funding environment is neither predictable nor sustainable for small companies,” said Batchelor, “and support from the North Carolina Biotechnology Center is critical for NovaTarg to become established as a local drug-discovery company.

“NovaTarg is making great strides toward the identification of our first drug candidate for the treatment of hepatitis C and other liver-associated diseases. We look forward to using the CIL to fund key aspects of this discovery effort. NovaTarg has also received grant funding from the National Institutes of Health to help further its research.”

Joseph Nixon, business development director at the Biotech Center, who manages the Company Inception Loan program, said the current funding environment for early-stage biotechnology companies is extremely challenging.

“The Biotechnology Center is pleased to support NovaTarg at this critical time in the company’s development,” he said. “We expect that this funding will help the company create jobs in North Carolina and to develop important products addressing significant unmet needs for patients.”

The Biotechnology Center is a private, non-profit corporation supported by the N.C. General Assembly. Its mission is to provide long-term economic and societal benefits to North Carolina by supporting biotechnology research, business, education and strategic policy statewide.

Contact: Robin Deacle, vice president of corporate communications, at robin_deacle@ncbiotech.org or 919-541-9366. Visit the Biotechnology Center's website at www.ncbiotech.org



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES